• Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study 

      Ree, Anne Hansen; Nygaard, Vigdis; Pedersen, Kjetil Boye; Heinrich, Daniel; Dueland, Svein; Bergheim, Inger Riise; Johansen, Christin; Beiske, Klaus; Negård, Anne; Lund-Iversen, Marius; Nygaard, Vegard; Hovig, Eivind; Nakken, Sigve; Nasser, Salah; Julsrud, Lars; Reisse, Claudius; Ruud, Espen Asak; Kristensen, Vessela N.; Flørenes, Vivi Ann; Geitvik, Gry; Lingjærde, Ole Christian; Børresen-Dale, Anne-Lise; Russnes, Hege Elisabeth Giercksky; Mælandsmo, Gunhild Mari; Flatmark, Kjersti (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-03-25)
      <i>Background</i>: In precision cancer medicine, the challenge is to prioritize DNA driver events, account for resistance markers, and procure sufficient information for treatment that maintains patient safety. The MetAction project, exploring how tumor molecular vulnerabilities predict therapy response, first established the required workflow for DNA sequencing and data interpretation (2014–2015). ...